Thermo Fisher debuts swine flu test; Nexvet nabs biotech factory; Integrated Animal Health expands global footprint;

>Thermo Fisher ($TMO) announced it has launched a first-in-class diagnostic kit that can rapidly detect subtypes of swine influenza virus (SIV). Release

> Integrated Animal Health announced that it has opened offices in New Zealand and Hungary and signed an exclusive distribution agreement with Domhealth in New Zealand. Release

> Nexvet Biopharma ($NVET) has secured a 20,000-square-foot biologics manufacturing facility in Tullamore, Ireland. Release

> Premune, which is developing therapeutics for companion animals, has named Ed Torr, former executive director of Dechra Pharmaceuticals, as its new head of business development and commercial operations. Release

> PetCure Oncology, a provider of stereotactic radiosurgery to the veterinary market, has acquired Veterinary MRI and Radiotherapy Center of NJ. Release

> Anatara Lifesciences of Australia announced that in a field trial of Detach, a non-antibiotic therapy to treat scour in piglets, the number of animals with the condition dropped by 41% and the severity fell by 45%. Release (PDF)

> Researchers from the Friedrich-Loeffler-Institute in Germany have determined that an outbreak of Bovine Viral Diarrhea (BVD) that affected 5,000 cows and killed 500 was likely spread by veterinarians and farmers, according to a paper published in the new open access journal Heliyon. Release

> Supplement maker Vets Plus has named David Nelson president, with responsibility for production execution and operations. Release

> Vireo Systems of Tennessee has acquired Rejuvenate Plus, a Canadian manufacturer of supplements for dogs and cats. Release

> France launched a widespread livestock vaccination program after a case of bluetongue disease was found on a farm in the central region of the country. Article

> A study by scientists at the University of California at Berkeley found that 59% of tumor samples taken from women with breast cancer showed evidence of exposure to bovine leukemia virus, though they noted the results do not prove the virus causes cancer. Article

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…